Counterfeit GLP-1 schemes do not slow down when shortages are resolved
Kuwasako K, Hay DL, Nagata S, Murakami M, Kitamura K, Kato J
Man wrde dies an einem teilweisen Wirkverlust (grere Urinmenge, krzere Wirkung sowie eine helle Farbe des Urins) erkennen und wrde dies durch eine etwas hhere Dosis ausgleichen, bis eine neue Flasche vorliegt
1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17]
30 The delivery device for dulaglutide does not require the patient to attach a needle and it may therefore be the preferred agent for those who have poor dexterity or are needle phobic
In other words, it might need more process factors than peptide molecules with a single target